Trial Profile

Phase 1 single ascending dose / multiple ascending dose study assessing NMRA-266 in healthy adult participants

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 17 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Apr 2024 According to Neumora Therapeutics media release, company announced that this trial has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). The clinical hold determination follows recently available pre-clinical data showing convulsions in rabbits.
15 Apr 2024 According to Neumora Therapeutics media release, Neumora is working with the FDA to evaluate the potential to resolve the clinical hold. While these discussions with the Agency are ongoing, the Companys prior guidance regarding NMRA-266 is no longer applicable. Neumora will provide an update on NMRA-266 when available.
15 Apr 2024 According to Neumora Therapeutics media release, status changed from recruiting to suspended.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com